Investigations on biomarker search in patients with non-small-cell bronchial carcinoma under checkpoint inhibitor therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022767

Enrollment

100

Registered

2020-10-08

Start date

2019-06-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34.9

Interventions

Group 1: advanced NSCLC with indication for palliative immunotherapy with or without chemotherapy - determination of the immune cell repertoire in the blood of patients with NSCLC at different points

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients must be able to give consent themselves - signed consent form - histologically confirmed NSCLC with indication for palliative immunotherapy with or without chemotherapy

Exclusion criteria

Exclusion criteria: - histologically confirmed SCLC - previous immunotherapies

Design outcomes

Primary

Measure	Time frame
progressionfree survival - controll via CT and MRI after 4th cycle of immunotherapy and afterwards every 3 month or if there is clinical indication of progress	—

Secondary

Measure	Time frame
Overall survival - controll every 3 month - acquiation via Klinisches Krebsregister or genaral practitioner	—

Countries

Germany

Contacts

Public ContactWolfgang Schütte

Krankenhaus Martha-Maria Halle-Dölau

Innere-Medizin2.Halle@Martha-Maria.de0345-559 1440

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026